0001225208-13-001248.txt : 20130109 0001225208-13-001248.hdr.sgml : 20130109 20130109174433 ACCESSION NUMBER: 0001225208-13-001248 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20130101 FILED AS OF DATE: 20130109 DATE AS OF CHANGE: 20130109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ballinger Kevin J. CENTRAL INDEX KEY: 0001566080 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 13521235 MAIL ADDRESS: STREET 1: C/O BOSTON SCIENTIFIC CORPORATION STREET 2: ONE BOSTON SCIENTIFIC PLACE CITY: NATICK STATE: MA ZIP: 01760 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE BOSTON SCIENTIFIC PL CITY: NATICK STATE: MA ZIP: 01760-1537 BUSINESS PHONE: 508-650-8000 MAIL ADDRESS: STREET 1: ONE BOSTON SCIENTIFIC PL CITY: NATICK STATE: MA ZIP: 01760-1537 3 1 doc3.xml X0206 3 2013-01-01 0 0000885725 BOSTON SCIENTIFIC CORP BSX 0001566080 Ballinger Kevin J. ONE BOSTON SCIENTIFIC PLACE NATICK MA 01760-1537 1 SVP & Pres, Interven Cardio Common Stock 91825.0000 D Deferred Stock Units 2013-02-12 Common Stock 5913.0000 D Deferred Stock Units 2015-02-16 Common Stock 34413.0000 D Deferred Stock Units 2014-02-24 Common Stock 6291.0000 D Deferred Stock Units 2017-02-27 Common Stock 15924.0000 D Deferred Stock Units 2016-02-28 Common Stock 22346.0000 D Deferred Stock Units 2013-10-28 Common Stock 2594.0000 D Stock Option (Right to Buy) 6.2800 2022-02-27 Common Stock 37497.0000 D Stock Option (Right to Buy) 6.3100 2020-10-25 Common Stock 100000.0000 D Stock Option (Right to Buy) 7.1600 2021-02-28 Common Stock 62112.0000 D Stock Option (Right to Buy) 7.4100 2020-02-16 Common Stock 23077.0000 D Stock Option (Right to Buy) 7.7100 2018-10-28 Common Stock 36630.0000 D Stock Option (Right to Buy) 8.3000 2019-02-24 Common Stock 35000.0000 D Stock Option (Right to Buy) 15.9100 2016-10-31 Common Stock 17100.0000 D Stock Option (Right to Buy) 21.7800 2013-02-25 Common Stock 8000.0000 D Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 12, 2009, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on February 12, 2008, which will continue to vest in one remaining installment on the anniversary of the date of grant. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 16, 2011, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on February 16, 2010, which will continue to vest in three equal annual installments on the anniversary of the date of grant. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2010, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on February 24, 2009, which will continue to vest in two equal annual installments on the anniversary of the date of grant. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2012, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on February 28, 2011, which will continue to vest in four equal annual installments on the anniversary of the date of grant. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 28, 2009, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on October 28, 2008, which will continue to vest in one remaining installment on the anniversary of the date of grant. Grant to the reporting person of an option to purchase 37,497 shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase 100,000 shares of common stock vesting in four equal annual installments beginning on October 25, 2011, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase 62,112 shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase 23,077 shares of common stock vesting in four equal annual installments beginning on February 16, 2011, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase 36,630 shares of common stock on October 28, 2008. This option is fully vested. Grant to the reporting person of an option to purchase 35,000 shares of common stock vesting in four equal annual installments beginning on February 24, 2010, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase 17,100 shares of common stock on October 31, 2006. This option is fully vested. Grant to the reporting person of an option to purchase 8,000 shares of common stock on February 25, 2003. This option is fully vested. poaballinger.txt /s/ Conor Kilroy, Attorney-in-Fact 2013-01-09 EX-99 2 poaballinger.txt POWER OF ATTORNEY Know all by these present that the undersigned hereby constitutes and appoints each of Timothy A. Pratt, Vance R. Brown, Theresa R. Boni, Todd D. Hammond and Conor Kilroy signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer and/or director of Boston Scientific Corporation (the "Company"), Forms 3, 4 and 5, and amendments thereto, in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; (3) execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer and/or director of the Company, Forms 144 in accordance with Rule 144 of the Securities Act of 1933, as amended, and the rules and regulations thereunder; and (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 or Rule 144 of the Securities Act of 1933, as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 and Forms 144 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 30th day of December, 2012. /s/ Kevin J. Ballinger Kevin J. Ballinger